

FLUAD® Quad is an inactivated influenza vaccine, with an MF59® Adjuvant. FLUAD® Quad is an unfunded Prescription Medicine, a charge will apply. FLUAD® Quad is for active immunisation against influenza for people aged 65 years and older. Each dose contains 60 micrograms/0.5 mL of surface antigens from four influenza virus strains. FLUAD® Quad has risks and benefits. Ask your doctor if FLUAD® Quad is right for you. Common side effects: injection site reactions e.g. pain, swelling, and redness warmth, burning or stinging, bruising. Fatigue, headache, aching muscles or joints, diarrhoea, chills, nausea, loss of appetite, vomiting fever. Very rarely, Guillain-Barré syndrome (feeling weak, numbness and tingling in your limbs). Tell your healthcare professional if you have ever had an allergic reaction to any vaccine, egg or to any of the listed ingredients for FLUAD® Quad. If you experience side effects after being given FLUAD® Quad, talk to your doctor, pharmacist or healthcare professional. Additional product consumer information on FLUAD® Quad can be found at www.medsafe.govt.nz, CSL Seqirus, Auckland or 0800 502 757. FLUAD® and FLUAD® Quad are registered trademarks of Seqirus UK Ltd. 10/23
NZ-FLU-24-0034. TAPS NP22001. INSIGHT 13364

CSL Seqirus

CSL Seqirus

ADVANCED FLU VACCINES

RECOMMEND FLUAD® QUAD

The flu vaccine optimised for 65+[1,2]

FLUAD® QUAD influenza vaccine, adjuvanted

FLUAD Quad, the flu vaccine that contains MF59® Adjuvant, is available for the 2025 flu season as an unfunded option for patients aged 65 years and older.[1]

Observational studies in individuals aged 65+, showed improved vaccine effectiveness in protecting against the flu compared with the standard egg-based influenza vaccine:[†3-5]

Lower risk
of medical encounters due to influenza-related outcomes, including hospitalisations, ER visits and GP visits[3-5*]

Up to 36% reduction[‡]
in influenza-related GP visits[4,6,7]

Longer protection
Antibody levels are higher at 12 months post vaccination[†8]

335 million+
doses distributed worldwide[^9]

*Compared to non-adjuvanted, standard egg-based influenza vaccines. ^Dose count includes doses distributed globally as of June 2024 and includes both FLUAD Trivalent and FLUAD Quad. †No effectiveness randomised clinical studies have been performed with FLUAD Quad versus standard dose quadrivalent influenza vaccine. The observational effectiveness studies performed with FLUAD (trivalent formulation) are relevant to FLUAD Quad as both vaccines are manufactured using the same process and have overlapping compositions. Observational studies have limitations including potential for selection bias, residual confounding. Studies were conducted in different seasons with different circulating strains. Influenza infection was not laboratory confirmed in all studies. ‡Influenza-related office visits; 25% [95% CI: 17.0, 32.2] against standard dose trivalent influenza vaccine, 36.3% [95% CI: 31.0, 41.2] against standard dose quadrivalent influenza vaccine.

References: 1. Seqirus NZ. FLUAD® Quad Data Sheet. Seqirus (NZ) Ltd. October 2023. 2. Podda A. Vaccine. 2001;19(17-19):2673-2680. 3. Lapi F, et al. Expert Review of Vaccines. 2022 Sep 8;21(11):1647-53. 4. Gärtner BC, et al. Vaccine.2022;40(22):2999-3008. 5. Coleman BL et al. Influenza Other Respir Viruses. 2021;15(6):813-823. 6. Pelton SI, et al. Vaccines (Basel).2020;8(3):E446. 7. Boikos C, et al.Clin Infect Dis.2021;73(5):816-823 8. Frey SE et al. Vaccine. 2014;32(39):5027-5034. 9. Data on File #8. Seqirus Inc; 2024.

FLUAD® Quad is an unfunded Prescription Medicine. FLUAD® Quad is an inactivated influenza vaccine, with an MF59® Adjuvant, as a suspension for injection in a single-dose glass syringe. **PRESENTATION:** Each dose contains 60 micrograms/0.5 mL of surface haemagglutinin and neuraminidase from four influenza virus strains **INDICATIONS:** For active immunisation against seasonal influenza for people 65 years of age and older. **CONTRAINDICATIONS:** Known severe allergic reactions to any component of the vaccine, except egg proteins; previous dose of any influenza vaccine. **ADVERSE EVENTS:** ***Common*** injection site pain, fatigue and headache. Most of these reactions disappear within 3 days. ***Rare*** but serious events include thrombocytopenia; lymphadenopathy; muscular weakness; allergic reactions such as anaphylactic shock, anaphylaxis; encephalomyelitis, Guillain Barré syndrome, neuritis, neuralgia, paraesthesia, convulsions; vasculitis with transient renal involvement; generalised skin reactions; and severe injection-site reactions (extensive limb swelling or cellulitis-like reactions). **PRECAUTIONS:** Postpone immunisation in patients with acute febrile illness or infection. Antibody responses may not be protective in all vaccinees, particularly in immunosuppressed patients. FLUAD® Quad is for intramuscular injection use only. Persons with a history of anaphylaxis to egg should be vaccinated only in medical facilities with staff experienced in recognising and treating anaphylaxis. Co-administration with other vaccines has not been studied. If Guillain-Barré syndrome has occurred within 6 weeks of previous influenza vaccination, consider potential benefits and risks. **DOSAGE AND ADMINISTRATION:** Gently shake before use; inject a single 0.5 mL dose into the deltoid muscle. Store at 2–8°C; do not freeze; protect from light. Before prescribing, review the FLUAD® Quad Data Sheet at www.medsafe.govt.nz, or from CSL Seqirus (NZ) Ltd, Auckland. FLUAD® and FLUAD® Quad are registered trademarks of Seqirus UK Ltd. 10/23 NZ-FLU-24-0033. TAPS DA2414ER. INSIGHT 13362

CSL Seqirus